Thomas E. Mabry

1.1k total citations
13 papers, 185 citations indexed

About

Thomas E. Mabry is a scholar working on Molecular Biology, Pharmacology and Oncology. According to data from OpenAlex, Thomas E. Mabry has authored 13 papers receiving a total of 185 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 3 papers in Pharmacology and 3 papers in Oncology. Recurrent topics in Thomas E. Mabry's work include Alzheimer's disease research and treatments (2 papers), Computational Drug Discovery Methods (2 papers) and Cancer therapeutics and mechanisms (2 papers). Thomas E. Mabry is often cited by papers focused on Alzheimer's disease research and treatments (2 papers), Computational Drug Discovery Methods (2 papers) and Cancer therapeutics and mechanisms (2 papers). Thomas E. Mabry collaborates with scholars based in United States. Thomas E. Mabry's co-authors include C. David Jones, Joseph M. Colacino, Kirk A. Staschke, James E. Audia, Patrick C. May, Jeffrey S. Nissen, Larry C. Blaszczak, Mark H. Bender, Thomas A. Crowell and Paul A. Hyslop and has published in prestigious journals such as Journal of Medicinal Chemistry, Antimicrobial Agents and Chemotherapy and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Thomas E. Mabry

12 papers receiving 185 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas E. Mabry United States 9 69 48 40 35 34 13 185
Marilyn Zeman Canada 5 150 2.2× 99 2.1× 46 1.1× 11 0.3× 17 0.5× 9 322
Bhaumik A. Pandya United States 8 145 2.1× 34 0.7× 73 1.8× 10 0.3× 39 1.1× 11 235
Dulce Garrido United States 11 222 3.2× 23 0.5× 183 4.6× 48 1.4× 18 0.5× 18 427
Jerry Meng United States 5 113 1.6× 28 0.6× 25 0.6× 39 1.1× 19 0.6× 5 163
Lisa R. Thompson United Kingdom 7 155 2.2× 22 0.5× 103 2.6× 59 1.7× 19 0.6× 8 289
Donna Skow United States 8 139 2.0× 8 0.2× 74 1.9× 11 0.3× 22 0.6× 10 269
Mitchell P. Christy United States 7 104 1.5× 18 0.4× 42 1.1× 18 0.5× 19 0.6× 8 197
Eric Garver United States 9 40 0.6× 9 0.2× 26 0.7× 10 0.3× 31 0.9× 10 186
Yury Kapelyukh United Kingdom 9 123 1.8× 18 0.4× 10 0.3× 37 1.1× 13 0.4× 15 355
Neeraj Masand India 8 70 1.0× 12 0.3× 95 2.4× 80 2.3× 63 1.9× 32 265

Countries citing papers authored by Thomas E. Mabry

Since Specialization
Citations

This map shows the geographic impact of Thomas E. Mabry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas E. Mabry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas E. Mabry more than expected).

Fields of papers citing papers by Thomas E. Mabry

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas E. Mabry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas E. Mabry. The network helps show where Thomas E. Mabry may publish in the future.

Co-authorship network of co-authors of Thomas E. Mabry

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas E. Mabry. A scholar is included among the top collaborators of Thomas E. Mabry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas E. Mabry. Thomas E. Mabry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
2.
Estridge, Thomas, Asim Dey, Charles A. Reidy, et al.. (2017). Identification of 4-Aminopyrazolopyrimidine Metabolite That May Contribute to the Hypolipidemic Effects of LY2584702 in Long Evans Diet–Induced Obese Rats. Journal of Pharmacology and Experimental Therapeutics. 362(1). 108–118. 4 indexed citations
3.
Leohr, Jennifer, Debra Luffer‐Atlas, Mengdie Luo, et al.. (2017). Serum Lipid and Protein Changes in Healthy Dyslipidemic Subjects Given a Selective Inhibitor of p70 S6 Kinase‐1. The Journal of Clinical Pharmacology. 58(4). 412–424. 2 indexed citations
4.
Carson, Matthew W., J.G. Luz, Chen S. Suen, et al.. (2014). Glucocorticoid Receptor Modulators Informed by Crystallography Lead to a New Rationale for Receptor Selectivity, Function, and Implications for Structure-Based Design. Journal of Medicinal Chemistry. 57(3). 849–860. 25 indexed citations
5.
Hyslop, Paul A., Patrick C. May, James E. Audia, et al.. (2004). P1-180 Reduction in a-beta(1-40) and A-beta(1-42) in CSF and plasma in the beagle dog following acute oral dosing of the gamma secretase inhibitor, LY450139. Neurobiology of Aging. 25. S147–S147. 12 indexed citations
6.
Gitter, Bruce D., Dan L. Czilli, Weiying Li, et al.. (2004). P4-339 Stereoselective inhibition of amyloid beta peptide secretion by LY450139, a novel functional gamma secretase inhibitor. Neurobiology of Aging. 25. S571–S571. 21 indexed citations
7.
Boggs, Leonard N., Kimberly S. Fuson, Bruce D. Gitter, et al.. (2004). P1-419 In vivo characterization of LY450139, a novel, stereoselective, functional gamma-secretase inhibitor. Neurobiology of Aging. 25. S218–S218. 12 indexed citations
8.
Garofalo, Albert W., James E. Audia, Harry F. Dovey, et al.. (2002). A series of C-Terminal amino alcohol dipeptide Aβ inhibitors. Bioorganic & Medicinal Chemistry Letters. 12(21). 3051–3053. 17 indexed citations
9.
Staschke, Kirk A., Joseph M. Colacino, Thomas E. Mabry, & C. David Jones. (1994). The in vitro anti-hepatitis B virus activity of FIAU [1-(2′-deoxy-2′-fluoro-1-β-d-arabinofuranosyl-5-iodo)uracil] is selective, reversible, and determined, at least in part, by the host cell. Antiviral Research. 23(1). 45–61. 34 indexed citations
10.
Bowsher, Ronald R., et al.. (1994). Sensitive and specific radioimmunoassay for fialuridine: initial assessment of pharmacokinetics after single oral doses to healthy volunteers. Antimicrobial Agents and Chemotherapy. 38(9). 2134–2142. 20 indexed citations
11.
Mabry, Thomas E., C. David Jones, Tse‐Chuan Chou, et al.. (1994). Synthesis of 4-Amino-8-(2, 2-Difluoro-2-Deoxy-β-D-Ribo Furanosyl Amino)Pyrimido [5, 4-D]Pyrimidine (dFARPP). Stability and Cellular Cytotoxicity. Nucleosides and Nucleotides. 13(5). 1125–1133. 13 indexed citations
12.
13.
Wheeler, William J., Thomas E. Mabry, & C. David Jones. (1991). The synthesis of the 2H, 3H, and 14C‐isotopomers of 2′‐deoxy‐2′,2′‐difluorocytidine hydrochloride, an anti‐tumor compound. Journal of Labelled Compounds and Radiopharmaceuticals. 29(5). 583–589. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marilyn Zeman Breakdown of academic impact, for papers by Bhaumik A. Pandya Breakdown of academic impact, for papers by Dulce Garrido Breakdown of academic impact, for papers by Jerry Meng Breakdown of academic impact, for papers by Lisa R. Thompson Breakdown of academic impact, for papers by Donna Skow Breakdown of academic impact, for papers by Mitchell P. Christy Breakdown of academic impact, for papers by Eric Garver Breakdown of academic impact, for papers by Yury Kapelyukh Breakdown of academic impact, for papers by Neeraj Masand
Rankless by CCL
2026